Tag: Afinitor

10 Highlights for the Carcinoid and Neuroendocrine Tumor Community

• PET/CT using Gallium-68 DOTATOC captures hidden source of neuroendocrine cancer. “An investigational molecular imaging technique could be the key to finding the elusive primary tumor, say presenters at the 2015 Annual Meeting of the Society

10 Highlights of the Year 2011 for the Carcinoid and Neuroendocrine Tumor Community

As the Carcinoid Cancer Foundation looks back on the year 2011, there were many significant events and advances for the carcinoid and neuroendocrine tumor (NET) community.  Here are 10 of the year’s important stories:

1)     The FDA approved the first…

Pancreatic Neuroendocrine Tumors: A Rare Cancer

From your next door neighbor to Steve Jobs, co-founder of Apple who just announced that he is stepping down as CEO of the company, pancreatic neuroendocrine tumors (pNETs) affect less than 1 person in 100,000 in the United States.  This rare cancer is often…

Breaking News: FDA Approves Treatment for pNET Patients

For the first time in nearly three decades, there is a new treatment for pancreatic neuroendocrine tumor patients!  The Food and Drug Administration (FDA) today announced its approval of Afinitor© for pNET patients.  This is a milestone for the carcinoid/NET…

Carcinoid Cancer Foundation to Speak on Behalf of NET Cancer Patients at April 12, 2011 FDA Oncologic Drugs Advisory Committee Meeting

Grace Goldstein, Chief Operating Officer of the Carcinoid Cancer Foundation, will speak at the Open Public Hearing segment during the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee Meeting on April 12, 2011 in Silver …